| micelle |
prostate cancer |
PCa cells |
SREBP1 |
100 |
+20.3 to +26.9 |
|
high cellular uptake
via lysosome escape, and suppressing invasion,
metastasis and proliferation of cancer cells |
(278) |
| polymeric NPs |
prostate cancer |
PC-3 cell line |
GRP78 |
39.7 |
–24.2 |
83.8 (DTX) |
targeted delivery using
RGD segment, high biocompatibility,
excellent EE, prolonged-release and high antitumor activity |
(279) |
| 82.4 (siRNA) |
| chitosan NPs |
breast cancer |
Mucin1+ SKBR3 and mucin1– CHO cells |
cMET |
110.5 |
+11.6 |
90.7 (siRNA) |
high cellular uptake, effective down-regulation
of cMET, suppressing the expression of STAT3, IL-8, MMP-2, MMP-9,
and VEGF, leading to a decrease in invasion and proliferation of cancer
cells |
(280) |
| 88.3 (DTX) |
| chitosan NPs |
breast
cancer |
SKBR3 breast cancer cells |
IGF-1R |
110–118 |
+12 to +14 |
91.2 (siRNA) |
high cellular uptake, reducing cancer viability,
and down-regulation of IGF-1R, STAT3, MMP-9 and VEGF |
(281) |
| 87.6 (DTX) |
| liposome |
laryngeal cancer |
Hep-2 cells |
ABCG2 |
180 |
|
|
inhibiting
tumor growth for in vitro and in vivo |
(282) |
| polymeric NPs |
nasopharyngeal carcinoma |
HEN-1 cells |
MMP-9 |
|
|
|
down-regulation
of MMP-9, stimulation of apoptosis and suppressing
metastasis |
(283) |
